Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV prevention in MEC (KMEC)
NCT01636947Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Dec 2012; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01636947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636947.